NASDAQ: XWELXwell Inc Stock
$0.69+0.00 (+0%)
Updated Oct 30, 2026
XWEL Price
$0.69
Fair Value Price
N/A
Market Cap
$5.93M
52 Week Low
$0.26
52 Week High
$2.20
P/E
-0.13x
P/B
-3.2x
P/S
0.31x
PEG
N/A
Dividend Yield
N/A
Revenue
$28.28M
Earnings
-$23.45M
Gross Margin
34.3%
Operating Margin
-82.62%
Profit Margin
-117.8%
Debt to Equity
-6.62
Operating Cash Flow
-$11M
Beta
0.7
Next Earnings
Nov 13, 2026
Ex-Dividend
N/A
Next Dividend
N/A
XWEL Overview
XWELL Inc. functions as a health and wellness services provider, primarily operating within airports. The company delivers its diverse offerings through various brands, including XpresSpa, XpresTest, Treat, and HyperPointe. Its core services feature a range of spa treatments such as massages, nail care, and skincare, further complemented by the sale of spa, travel, and general retail merchandise. Beyond relaxation services, XWELL also manages dedicated wellness centers. These facilities provide crucial health diagnostic services, encompassing COVID-19 screening and testing, rapid tests for various communicable diseases like influenza, RSV, and different flu strains (A&B), alongside seasonal flu vaccinations and other medical diagnostic procedures. To enhance accessibility for the traveling public, the company utilizes an integrated digital platform and a tailored retail selection. The organization, headquartered in New York, New York, underwent a name change in October 2022, transitioning from its former identity as XpresSpa Group, Inc. to its current designation, XWELL Inc.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine XWEL's potential to beat the market
- XWEL doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
B
XWEL
RankedUnranked of 40
RankedUnranked of 40
Be the first to know about important XWEL news, forecast changes, insider trades & much more!
XWEL News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how XWEL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
XWEL is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
XWEL is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
XWEL's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more XWEL due diligence checks available for Premium users.
Valuation
XWEL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.13x
Industry
11.13x
Market
46.28x
XWEL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-3.2x
Industry
4.92x
XWEL's financial health
Profit margin
Revenue
$7.1M
Net Income
-$2.2M
Profit Margin
-31.4%
XWEL's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
XWEL's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$20.5M
Liabilities
$12.3M
Debt to equity
-6.62
XWEL's short-term assets ($15.14M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
XWEL's short-term assets ($15.14M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
XWEL's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
XWEL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.5M
Investing
-$162.0k
Financing
$0.0
XWEL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
XWEL vs Diagnostic & Research Stocks
Xwell Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.